Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.36 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 8/20 | 0.35 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152594 | 0.89 | CNR1 (0.37) | CYP2C9CYP2C19PDK2CNR1CNR2 | |
| SCHEMBL19153246 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL3530263 | 0.86 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19153026 | 0.86 | CNR1 (0.40) | PDK2CNR1CNR2 | |
| SCHEMBL19153180 | 0.83 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19153489 | 0.81 | CNR1 (0.41) | PDK2CNR1CNR2PTPN11 | |
| SCHEMBL1994589 | 0.80 | PDK2 (0.41) | PDK2PTPN11 | |
| SCHEMBL19152845 | 0.79 | HSP90AA1 (0.40) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL22184022 | 0.78 | PDK2 (0.35) | PDK2CNR1CNR2 | |
| SCHEMBL21527563 | 0.78 | PDK2 (0.35) | PDK2CNR1CNR2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204129-A1 | NOVEL TRANSITION METAL COMPOUND, TRANSITION METAL CATALYST COMPOSITION FOR POLYMERIZING OLEFIN, CONTAINING SAME, AND METHOD FOR PREPARING ETHYLENE HOMOPOLYMER OR COPOLYMER OF ETHYLENE AND ALPHA-OLEFIN BY USING SAME | SABIC SK NEXLENE COMPANY PTE. LTD. (SG) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204129-A1 | NOVEL TRANSITION METAL COMPOUND, TRANSITION METAL CATALYST COMPOSITION FOR POLYMERIZING OLEFIN, CONTAINING SAME, AND METHOD FOR PREPARING ETHYLENE HOMOPOLYMER OR COPOLYMER OF ETHYLENE AND ALPHA-OLEFIN BY USING SAME | ETFA, ETFB, EMC2 | CYP1A2 1607/4885CYP3A4 985/4885CYP2C9 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.